Lord, Abbett & Co
TEVA icon

Lord, Abbett & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Lord, Abbett & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66M Sell
1,947,806
-464,530
-19% -$15.5M 0.19% 141
2026
Q1 		$72.7M Sell
2,412,336
-1,037,271
-30% -$33.4M 0.24% 117
2025
Q4 		$108M Sell
3,449,607
-26,356
-0.8% -$649K 0.33% 82
2025
Q3 		$70.2M Sell
3,475,963
-105,676
-3% -$1.86M 0.21% 132
2025
Q2 		$60M Buy
3,581,639
+811,519
+29% +$13.1M 0.19% 135
2025
Q1 		$42.6M Buy
2,770,120
+365,225
+15% +$6.52M 0.15% 169
2024
Q4 		$53M Buy
2,404,895
+960,648
+67% +$17.5M 0.17% 159
2024
Q3 		$26M Sell
1,444,247
-188,753
-12% -$3.3M 0.08% 282
2024
Q2 		$26.5M Buy
+1,633,000
New +$25.2M 0.09% 276
2016
Q4 		– Sell
-48,757
Closed -$2.24M – 955
2016
Q3 		$2.24M Sell
48,757
-37,666
-44% -$1.97M 0.01% 825
2016
Q2 		$4.34M Sell
86,423
-367
-0.4% -$19.5K 0.01% 741
2016
Q1 		$4.64M Sell
86,790
-91,509
-51% -$5.37M 0.01% 722
2015
Q4 		$11.7M Buy
178,299
+6,386
+4% +$395K 0.04% 558
2015
Q3 		$9.71M Buy
+171,913
New +$11.1M 0.03% 594
2014
Q4 		– Sell
-213,000
Closed -$11.4M – 977
2014
Q3 		$11.4M Sell
213,000
-74,200
-26% -$3.93M 0.03% 580
2014
Q2 		$15.1M Buy
287,200
+16,000
+6% +$818K 0.03% 564
2014
Q1 		$14.3M Buy
+271,200
New +$12.5M 0.03% 550

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Lord, Abbett & Co's TEVA Position: Q2 2026 in Review

Lord, Abbett & Co reduced its Teva Pharmaceuticals (TEVA) stake by 19% in Q2 2026, selling an estimated $15.5M and leaving 1,947,806 shares worth $66M. The position accounts for 0.19% of the portfolio, ranked #141.

Lord, Abbett & Co first reported a position in TEVA in Q1 2014 and has held it in 17 quarters since. The position peaked at $108M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Lord, Abbett & Co held 1,947,806 shares of Teva Pharmaceuticals worth $66M as of Q2 2026.
  • Lord, Abbett & Co sold 464,530 Teva Pharmaceuticals shares in Q2 2026, an estimated $15.5M.
  • Teva Pharmaceuticals made up 0.19% of Lord, Abbett & Co's portfolio in Q2 2026, its #141 holding.
  • Lord, Abbett & Co first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 17 quarters since.
  • Lord, Abbett & Co's Teva Pharmaceuticals position peaked at $108M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.